tbuckley/cabot-search huggingface dataset:
Optimal treatment for untreated patients with hairy cell leukemia?
Authors: X Troussard, G Flandrin
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.10.2677 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7595722 Optimal treatment for untreated patients with hairy cell leukemia? X TroussardxX TroussardSearch for articles by this author , G FlandrinxG FlandrinSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.10.2677 First Page PDF © 1995 by American Society of Clinical Oncology
Runt Syndrome Induced in the Rat by Polyinosinic·Polycytidylic Acid 2
Authors: Anthony J. Cecalupo, John W. Kreider, Martha E. Noggle
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Runt Syndrome Induced in the Rat by Polyinosinic·Polycytidylic Acid Get access Anthony J. Cecalupo, Anthony J. Cecalupo Search for other works by this author on: Oxford Academic PubMed Google Scholar John W. Kreider, John W. Kreider Search for other works by this author on: Oxford Academic PubMed Google Scholar Martha E. Noggle Martha E. Noggle Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 1, January 1975, Pages 129–136, https://doi.org/10.1093/jnci/54.1.129 Published: 01 January 1975 Article history Received: 11 June 1974 Accepted: 16 September 1974 Published: 01 January 1975
PTH-129 Nutrition status pre liver transplant and length of hospital stay post liver transplant
Authors: N O’Sullivan, DD Houlihan
Journal: Gut (2015)

<h3>Introduction</h3> ESPEN states that under-nutrition is a major factor influencing outcomes after orthotopic liver transplant (OLT). Early detections and interventions to correct nutritional deficits may help shorten length of hospital stay (LOS) post OLT. <h3>Aim</h3> To determine if there is a relationship between nutritional parameters pre OLT and i) total LOS post OLT ii) intensive care (ICU) LOS post OLT. The primary outcome measures were total hospital LOS and ICU LOS. Secondary aims included measuring the degree of malnutrition in those with and without a cancer diagnosis as aetiology for OLT. <h3>Method</h3> The study design was retrospective analysis. Approval was received from the hospital audit committee. All patients who were alive at discharge after an elective first OLT between January 2009 and December 2014 were identified. Data was prospectively gathered when nutritional status was assessed within 100 days pre transplant by a Dietitian. Data was retrospectively analysed on the following nutrition parameters; 1) dry BMI at OLT 2) hand grip strength (HGS) 3) Royal Free Hospital Global Assessment (RFH-GA). Statistical analysis including descriptive statistics, Spearman’s Correlation and the Mann-Whitney test to compare groups were undertaken. <h3>Results</h3> 226 patients underwent their first elective OLT and survived to discharge. 76% of the patients were transplanted for decompensated cirrhosis and 24% for cancer. The incidence of malnutrition as defined by RFH-GA was 64% pre OLT. The median BMI and%HGS of all OLTs was 25 Kg/m<sup>2</sup>[n = 200, range 15.1–41.1] and 75% [n = 84, range 28–151] respectively. The relationship between BMI and LOS had a weak negative association [r= –0.17, n = 200, p = 0.014]. Specifically patients with a BMI &lt; 20 had a longer overall LOS compared to those with BMI &gt;20 [21 days VS 17 days, p = 0.009]. The relationship between HGS pre OLT and LOS had a weak negative association [r= –0.247, n = 84, p = 0.024]. Specifically patients with a HGS &lt;85% had a longer overall LOS compared to those with HGS greater or equal to 85% [19 days VS 16 days, n = 84, p = 0.02]. No association was found between HGS or dry BMI at OLT and ICU LOS. Pre transplant malnutrition was more prevalent in those transplanted for decompensated cirrhosis compared to those with cancer (75% VS 8%). The LOS for decompensated cirrhosis was longer than that for cancer [18 VS 15.5days, n = 226, p = 0.017]. <h3>Conclusion</h3> The study would indicate that malnutrition as defined by BMI &lt;20 or HGS &lt; 85% of population norms is associated with a longer hospital stay post liver transplant but not ICU LOS. Dietetic resources should be targeted to these patients pre liver transplant. <h3>Disclosure of interest</h3> None Declared.
Evaluation of therapist candidates
Authors: E J Lynn, J A Nordhoff
Journal: American Journal of Psychiatry (1975)

The authors describe one phase of a four-step procedure designed to more fully evaluate candidates for psychotherapist positions. All applicants must conduct an interview with a patient, which is observed and evaluated by a team of staff members to assess diagnostic skills. This procedure has not only proved valuable in the program for which it was designed but has been extended to other programs and proposed for use in peer review.
Brief Communication: Zinc Intake, Neoplastic DNA Synthesis, and Chemical Carcinogenesis in Rats and Mice
Authors: J. R. Duncan, I. E. Dreosti
Journal: JNCI Journal of the National Cancer Institute (1975)

DNA synthesis in a transplanted hepatoma induced by 3'-methyl-4-dimethylaminoazobenzene was significantly reduced (P less than 0.01) in rats maintained on diets low (0.4 mug/g) or high (greater than or equal to 500 mug/g) in zinc when compared with control animals given 60 mug zinc/g. 3-Methylcholanthrene-induced carcinogenesis was considerably lowered in mice receiving the same low or high zinc diets during the induction periods.
Nociceptive Signaling Contributes to Progenitor Cells Activation and Mobilization During Ischemia in Mice and Human Subjects
Authors: Silvia Amadesi, Orazio Fortunato, Carlotta Reni, Rajesh Katare, Marco Meloni, Raimondo Ascione, Gaia Spinetti, Elisa Cangiano, Marco Valgimigli, Paolo R Madeddu
Journal: Cardiovascular Research (2012)
Highly heterogeneous temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates, northern France
Authors: I Pelletier, D Rousset, V Enouf, None GROG, F Colbère-Garapin, S van der Werf, N Naffakh
Journal: Eurosurveillance (2011)

We assayed the temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates (n=23) and seasonal influenza A(H1N1) viruses (n=18) isolated in northern France in 2007/08 and 2008/09. All isolates replicated with a similar efficiency at 34 °C and 37 °C, and with a lower efficiency at 40 °C. The pandemic viral isolates showed a stronger heterogeneity in their ability to grow at the highest temperature, as compared with the seasonal isolates. No statistically significant difference in temperature sensitivity was observed between the pandemic viral isolates from severe and mild cases of influenza. Our data point to the impact of temperature sensitivity on the genetic evolution and diversification of the pandemic influenza A(H1N1) virus since its introduction into the human population in April 2009, and call for close surveillance of this phenotypic marker related to host and tissue tropism.
Distribution of Primary Lung Carcinomas in Relation to Time as Determined by Histochemical Techniques&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Doris L. Herman, M.D., Margaret Crittenden
Journal: JNCI Journal of the National Cancer Institute (1961)

The 1,037 neoplasms with an original anatomic diagnosis of primary pulmonary carcinoma that were observed at necropsy at the Los Angeles County Hospital from 1927–57 were reviewed. Of these, 956 met the criteria for inclusion in this study. The neoplasms were reclassified according to two criteria: 1) a modification of Liebow's method in which hematoxylin-and-eosin-stained sections were used; 2) that of the World Health Organization in which, in addition, sections specially stained to demonstrate mucin and keratin were used. In our series approximately 30 percent was poorly differentiated or undifferentiated and close to 10 percent was the uncommon giant and/or spindle-cell variant. Most of these undifferentiated and poorly differentiated neoplasms contained acid mucopolysaccharide and were classified as adenocarcinoma. The percentage distribution of the various histologic types, especially the adenocarcinoma group, differed significantly according to the criteria used. Our data agree with other published reports which show that the frequency of lung carcinoma is increasing disproportionately to all necropsies. However, the roles played by various histologic types differ among studies. Independent of criteria used in our series, the proportion of epidermoid carcinomas in men is not increasing, while the proportion of adenocarcinomas apparently is increasing. Our ratios of epidermoid and undifferentiated carcinomas to adenocarcinomas are decreasing, while ratios reported by Kreyberg and others are increasing. Although this contrast is due partially to difference in interpretations by pathologists as well as to variations in methods and criteria, the Los Angeles County Hospital material is undeniably different from that reported elsewhere. The reasons for these differences need explanation, and further studies of both clinical and necropsy material from the Los Angeles area are indicated.
Extrapulmonary Small Cell Carcinoma in Prostate
Authors: Mohamed H Sayed, Hussein R Farghaly, Nghi C Nguyen, Mostafa S Mostafa, Mohamed A Mekkawy, Medhat M Osman
Journal: Clinical Nuclear Medicine (2009)

A 57-year-old man was referred for an fluoro-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) study of a primary tumor after a poorly differentiated carcinoma with neuroendocrine features which was biopsied from the liver. A 4-phase abdominal CT showed a large liver right lobe mass, suspicious for hypovascular hepatocellular carcinoma. Esophagogastroduodenoscopy and endoscopic ultrasound showed normal findings. Colonoscopy revealed a benign sigmoid colon polyp. PET/CT showed FDG avid bilateral hepatic lobe lesions, disseminated bone lesions, and an intense focus in the prostate suspicious for a prostatic primary. However, PSA was within the normal range. Tissue sampling of the prostatic lesion revealed small cell carcinoma with neuroendocrine features.
Book: Pre-hospital Paediatric Life Support
Authors: Ian Barker
Journal: BMJ (2000)

Eds F Jewkes, P Lubas, K McCusker

BMJ Books, £22, pp 203

ISBN 0 7279 1419 7

———————

Rating: ★★★★ (if you do the course)

Measuring 125×85 mm and weighing in at 0.8 kg, this is no pocket reference book for those who find themselves resuscitating a child before the ambulance arrives or en route to hospital. This is the text book written primarily for the prehospital paediatric life support (PHPLS) course, one of the more recent additions to the growing number of didactic courses on resuscitation.

The authors have varying backgrounds, including paediatric accident and emergency, the ambulance and paramedic service, and anaesthesia. The book has 24 chapters and appendices logically arranged through introduction, life support, medical illness, trauma, and practical procedures.

Who will benefit from reading this book? It is accessible only to health professionals, being written in technical medical English rather than plain language and simplified concepts easily understood by parents, teachers, and children themselves. This medical text highlights the differences between children and adults and teaches a logical, ordered approach to the initial management of a severely ill or injured child. However, it is of limited value unless read by a practitioner stimulated by the anticipation of an impending PHPLS course. On successful completion of the course, the book may become a reference (the line drawings photocopy wonderfully on to acetate sheets for overhead presentations), but the core knowledge will be firmly in place.

The book can be easily and quickly read, and it is well illustrated and indexed. The meat in the sandwich is the middle section on life support and the management of a seriously ill and injured child; to find fault would be to nitpick; it is excellent. I am puzzled somewhat by the section on practical procedures; I suppose it is necessary in preparation for the course, but there is only one way to learn practical procedures and it's not from a book. My favourite chapter is “Scene Management,” which gave me some insight into the work of paramedic colleagues and made me grateful for my controlled hospital environment. Will someone please tell me the answer to example 1 at the end of this chapter?

This book will give any healthcare professional some instruction in the early management of a critically ill child. When read in conjunction with the PHPLS course it should provide practitioners with the skills andconfidencetomanagesuch patientsand to work as members of an effective team.
DOGMATISM IN MEDICINE.
Authors: R BURNAND
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of Tumor Growth on Serum Glycoprotein Concentrations in the Rat2
Authors: Henry E. Weimer, Frances A. Quinn, Jean Redlich-Moshin, Hisako Nishihara
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Effects of Tumor Growth on Serum Glycoprotein Concentrations in the Rat Get access Henry E. Weimer, Henry E. Weimer Search for other works by this author on: Oxford Academic PubMed Google Scholar Frances A. Quinn, Frances A. Quinn Search for other works by this author on: Oxford Academic PubMed Google Scholar Jean Redlich-Moshin, Jean Redlich-Moshin Search for other works by this author on: Oxford Academic PubMed Google Scholar Hisako Nishihara Hisako Nishihara Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 3, September 1957, Pages 409–417, https://doi.org/10.1093/jnci/19.3.409 Published: 01 September 1957 Article history Received: 03 May 1957 Published: 01 September 1957
Point: Interferon-α for Adjuvant Therapy for Melanoma Patients
Authors: Michael S. Sabel, Vernon K. Sondak
Journal: Journal of the National Comprehensive Cancer Network (2004)

Interferon-α is possibly the most controversial adjuvant therapy for any solid tumor, and multiple trials involving varying doses, routes, schedules, and formulations of interferon-α have increased the confusion. Clinicians are left in a quandary, because high-dose interferon-α-2b (HDI) remains the only FDA-approved adjuvant therapy for high-risk melanoma. Of the three prospective randomized trials involving high-dose interferon-α-2b, all show a significant improvement in disease-free survival and two show a significant improvement in overall survival. Despite this strong evidence, data from studies involving alternate doses, concerns regarding cost and toxicity, and the promise of future therapies have led opponents of interferon to overlook these results. Based on the available clinical evidence, however, high-dose interferon should be offered as standard care for patients with high-risk, resected melanoma. Informed patients who have elected to forego interferon and patients with lower risk lesions can be offered participation in clinical trials with a no-treatment control arm.
Why are back pain guidelines left on the sidelines? Three myths appear to be guiding management of back pain in sport
Authors: Ben Darlow, Peter B O'Sullivan
Journal: British Journal of Sports Medicine (2016)

Southee was diagnosed with an irritated disc in his back, after scans.1  Lower back tightness prompted shortstop Ian Desmond to have a shortened night Tuesday… “I just figured it would probably be smart just to get out of there and not create any further damage.”2  The harder Shawcross pushed himself in pre-season the more discomfort he found himself in, leaving no alternative but for him to undergo the operation.3  

These media reports highlight the problem of back pain in sport. From the reports it would appear that athletes' back symptoms are serious and linked to structural damage. Athletes appear to be managed with rest or limiting training and competition, early referral for advanced imaging that often leads to invasive treatments and a requirement that symptoms settle before full sporting participation can resume. Such an approach to management contradicts current guidelines for back pain.4 

Given the discrepancy between the management of back pain in athletes and the …
SAT0145 Long-Term Cost-Effectiveness Analysis of the Treatment with Infliximab, Etanercept and Adalimumab in Rheumatoid Arthritis Patients in Real-Life Clinical Practice
Authors: M. Cárdenas, S. de la Fuente, P. Font-Ugalde, M.C. Castro-Villegas, M. Romero-Gόmez, D. Ruiz-Vílchez, J. Calvo-Gutiérrez, R. Ortega-Castro, A. Escudero-Contreras, M.A. Casado, E. Collantes
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Anti-tumour necrosis factor-α agents are effective in the management of rheumatoid arthritis (RA) patients, but superiority among them has not been established. Also, long-term pharmacoeconomic studies examining the cost-effectiveness of biological agents in real-life clinical practice are scarce. <h3>Objectives</h3> To assess the efficiency, in terms of cost to achieve clinical remission (CR: DAS28 value&lt;2.6), of the treatment with infliximab, etanercept and adalimumab in a real clinical setting after two years of treatment. <h3>Methods</h3> All patients diagnosed of RA in a tertiary referral hospital attended through an interdisciplinary consensus protocol who started treatment with infliximab, etanercept or adalimumab between January 2007 and December 2012 were included. Data examined included demographic and clinical variables and use of direct health-care resources. Effectiveness was measured as the proportion of patients achieving CR after two years of treatment (DAS28 value&lt;2,6). Costs were assessed from the hospital perspective including the official drug acquisition costs and costs for diagnostic tests and different medical services, obtained from the Hospital9s economic management database. Cost-effectiveness was calculated dividing total direct healthcare costs by percentage of patients achieving clinical remission. <h3>Results</h3> 130 patients were included (55 on infliximab, 44 on etanercept and 31 on adalimumab). 45.20% of patients on adalimumab achieved clinical remission after two years, versus 29.1% on infliximab (p=0.133) and 22.7% on etanercept (p=0.040), with no significant differences between etanercept and adalimumab (p=0.475). Mean total health direct costs at two years were 29,857.67 €, 25,328.60 € and 23,309.09 € for adalimumab, infliximab and etanercept, respectively. The mean cost (IC95%) to achieve CR after two years with adalimumab, infliximab and etanercept were 66,057€ (48,038-84,076), 87,040 € (78,496-95,584) and 102,683€ (94,559-110,807) respectively. Adalimumab resulted more efficient than etanercept (p&lt;0,001) and infliximab (p=0,026), without statistically significant differences between etanercept and infliximab (p=0.086). <h3>Conclusions</h3> Adalimumab resulted the most efficient treatment to achieve clinical remission in patients with rheumatoid arthritis in real-life clinical practice conditions in our hospital during the period examined. <h3>Disclosure of Interest</h3> None declared
Psychosocial characteristics of "double depression"
Authors: I W Miller, W H Norman, M G Dow
Journal: American Journal of Psychiatry (1986)

Thirty-nine patients with "double depression" (major depression and dysthymia) were compared to 38 patients with recurrent major depression without dysthymia on a number of severity of illness, psychosocial, and biological variables. No significant differences were found on any psychosocial or biological measure.
OP0126 A Genome-Wide Association Study Identifies a New Locus Asociated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis
Authors: J. Tornero, A. Fernández-Nebro, F. Blanco, A. Ortiz, J.D. Cañete, J. Maymό, M. Alperi-Lόpez, B. Fernández-Gutierrez, A. Olivé, H. Corominas, A. Erra, M.I. Acosta Colman, A. Alonso, M. Lόpez-Lasanta, R. Tortosa, A. Julià, S. Marsal
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Anti-Tumor Necrosis Factor (Anti-TNF) drugs are biologic agents commonly used to treat rheumatoid arthritis (RA). However, there is considerable heterogeneity in the response to this therapy and approximately 25% of anti-TNF-treated patients do not show a significant clinical improvement. The high costs of this therapy and the possibility of alternative biologic treatments of similar efficacy are raising the need for biomarkers of response to anti-TNF therapy. <h3>Objectives</h3> We conducted a Genome-Wide Association Study (GWAS) to identify the genetic variation associated with the response to anti-TNF therapy in RA. <h3>Methods</h3> A total of 372 RA patients treated with an anti-TNF agent (adalimumab, etanercept or infliximab) as their first biologic therapy were recruited in the discovery phase. All patients were diagnosed as RA according to the ACR classification criteria, had &gt;2 years of follow-up since diagnosis and were naïve to any biologic therapy. All cases were Caucasian European and with all four grandparents born in Spain. An independent cohort of 245 RA patients treated with an anti-TNF therapy and also collected by the IMIDC was used to validate the most significant genetic associations from the GWAS. The patient recruitment criteria were the same as for the discovery phase. <h3>Results</h3> A total of 3 SNPs were found to meet the significance threshold in the GWASs. From these, the <i>MED15</i> association with etanercept reached a genome-wide level of statistical significance (<i>P</i>=1.24e-8). The other two highly significant associated loci were <i>ARMC2</i> (<i>P</i>=6.22e-8) <i>MAFB</i><i>P</i>=6.26e-8), and were found in the global and etanercept-infliximab GWASs, respectively. Using the independent patient cohort we validated the association at <i>MED15</i> with the response to etanercept (<i>P</i> &lt;0.05, same direction of effect) and found a suggestive evidence for <i>MAFB</i> (<i>P</i>=0.056, same direction of effect). <h3>Conclusions</h3> In the present GWAS we have identified a new genetic region associated with the response to anti-TNF therapy and we have found additional evidence for a previously associated locus. The results of this study are an important contribution to the pharmacogenetics of this prevalent disease. <h3>Disclosure of Interest</h3> None declared